Novartis | The Business Standard
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
THURSDAY, MAY 26, 2022
THURSDAY, MAY 26, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা

Novartis

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau
Coronavirus chronicle

Novartis working on pan-coronavirus oral treatment, CEO says

"Now I would have loved for some of our own clinical trials to have worked out, but they didn't. I mean, that's part of the deal," Novartis CEO Narasimhan said

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann
Global Economy

Novartis may divest generic unit Sandoz as price pressures mount

The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERSCharles Platiau
Coronavirus chronicle

Swiss drugmaker Novartis to help make Pfizer-Biontech Covid-19 vaccine

The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020/Reuters
Global Economy

Novartis trims sales outlook after hit from Covid disruptions

The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020/Reuters
Coronavirus chronicle

Novartis to provide 'no profit' Covid-19 drugs to low income countries

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017/ Reuters
World+Biz

Novartis faces key meeting in US bribery scandal after settling corruption case

A pharmacist displays a box of Hydroxychloroquine at the CHR Centre Hospitalier Regional de la Citadelle Hospital amid the coronavirus disease in Liege, Belgium, June16, 2020/ Reuters
Coronavirus chronicle

Novartis halts malaria drug trial against Covid-19 amid participant shortfall

Novartis donates safety gears to combat coronavirus
Covid-19 in Bangladesh

Novartis donates safety gears to combat coronavirus

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau
Coronavirus chronicle

Novartis inks deal to make Mass General Brigham's Covid-19 vaccine candidate

The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020/Reuters
Coronavirus chronicle

Novartis, US regulators agree to malaria drug trial against Covid-19

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017/ Reuters
Coronavirus chronicle

Malaria drug is biggest hope against coronavirus: Novartis CEO

A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange (NYSE) in New York, US, July 29, 2019/ Reuters
World+Biz

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker
World+Biz

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

  • Show More
The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab